

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 30.05.2025

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Vista Pharmaceuticals Limited (BE Scrip Code:524711)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Vista Pharmaceuticals Limited held on Friday, the 30th day of May, 2025, at 04.00 P.M. at the registered office of the Company, the Company the following were duly considered and approved by the Board:



1. Audited Financial results together with Statement of Assets and Liabilities and Statement of Cash flow for the quarter and year ended 31.03.2025 (enclosed).
2. Auditors Report along with declaration of unmodified opinion for the year ended 31.03.2025 (enclosed).
3. Appointment of M/s. LMN & Co., Chartered Accountants, as Internal Auditors of the Company for the Financial Year 2025-26.
4. Appointment of M/s. Aakashya Dubey & Co., Practicing Company Secretaries as Secretarial Auditors of the Company for a period of five (5) years for the financial years 2025-26 to 2029-30 (Brief profile attached)

The meeting of the Board of Directors commenced at 4.00 P.M.(IST) and concluded at 5.30 P.M. (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Vista Pharmaceuticals Limited



Dhananjaya Alli
Executive Director
(DIN: 00610909)



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttaia Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001

Date: 30.05.2025

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.



Unit: Vista Pharmaceuticals Limited (BE Scrip Code:524711)

I, Dhananjaya Alli, Executive Director of Vista Pharmaceuticals Limited hereby declare that, the Statutory Auditors of the company, M/s. A.M Reddy & D.R. Reddy, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on audited financial results of the company for year ended 31st March, 2025.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide. Circular No. CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,
For Vista Pharmaceuticals Limited

Dhananjaya Alli
Executive Director
(DIN: 00610909)

Annexure

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated November 11, 2024]

Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. LMN & Co., Chartered Accountants as Internal Auditor of the company for Financial Year 2024-25.
Date of appointment & Terms of appointment	For the Financial Year 2024-25.
Brief Profile	M/s. LMN & Co., Practicing Chartered Accountants, registered with the Institute of Chartered Accountants of India. The Firm is being managed by a team of competent and experienced professionals with rich experience.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated November 11, 2024]

Reason for change viz. appointment, resignation, removal, death or otherwise	M/s. Aakansha Dubey & Co., Practicing Company Secretaries as Secretarial Auditors of the Company for a period of five (5) Financial Year(s) i.e., from 2025-26 to 2029-30.
Date of appointment & Terms of appointment	30.05.2025 and for a period of five (5) Financial Year(s) i.e., from 2025-26 to 2029-30.
Brief Profile	M/s. Aakansha Dubey & Co., Practicing Company Secretaries registered with the Institute of Company Secretaries of India. The Firm is being managed by a team of competent and experienced professionals with rich experience
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081, Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com


Statement of Audited Standalone Financial Results for the Quarter and Year ended 31.03.2025

S.No.	Particulars	Quarter Ended			Amounts in Lakhs	
		31.03.2025	Preceding	31.03.2024	Year Ended	
		Audited	31.12.2024	Audited	31.03.2025	31.03.2024
		Un-Audited		Audited	Audited	
I.	Revenue from Operations	323.00	255.5	313.25	1,007.46	1,028.78
II.	Other Income	24.06	12.19	9.76	44.06	33.34
III.	Total income (I+II)	347.06	267.69	323.01	1,051.52	1,062.12
IV.	Expenses					
	(a) Cost of Materials consumed	269.44	204.76	149.35	789.82	888.25
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	44.78	0.77	44.78	0.77
	(c) Employee benefits expense	56.02	51.54	47.73	200.39	179.47
	(d) Finance Cost	20.63	22.26	27.79	96.40	121.98
	(e) Depreciation and amortisation expense	18.46	18.69	18.05	73.81	71.97
	(f) Other expenses	88.72	106.10	89.13	375.30	291.75
	(g) Prior Period Expenses	-	-	0.02	-	25.67
	Total Expenses	453.27	448.13	332.85	1,580.51	1,579.86
	Net Profit/(Loss) for the period (before tax, Exceptional and/or extraordinary items)	(106.21)	(180.44)	(9.84)	(528.98)	(517.74)
IV	Exceptional Items	-	-	-	-	-
VI	Net Profit/(Loss) for the period before tax, (after Exceptional and/or extraordinary items)	(106.21)	(180.44)	(9.84)	(528.98)	(517.74)
V	Tax expense					
VIII	Current Tax	-	-	-	-	-
	Deferred Tax	0.35	(48.21)	(18.91)	(107.12)	(66.54)
	Previous year Income tax adjustment	43.01	-	-	43.01	-
	Net Profit/(Loss) for the period after tax, (after Exceptional and/or extraordinary items)	(149.57)	(132.23)	9.07	(464.87)	(451.20)
VI	Other Comprehensive Income	(1.24)	2.63	(0.28)	2.11	0.29
X	Items that will not be reclassified to Profit or Loss	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-
	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(150.81)	(129.60)	8.79	(462.76)	(450.91)
VII	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,231.04	1,231.04	943.30	1,231.04	943.30
VIII.	Earnings Per Equity Share of face value of Rs.10/- each)					
IX	a) Basic EPS (In Rs.)	(0.79)	(0.07)	0.02	(0.79)	(1.03)
	b) Diluted EPS (In Rs.)	(0.79)	(0.07)	0.01	(0.79)	(0.74)

Notes:

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Friday, May 30th, 2025.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- The figures of the current quarter ended March 31, 2025 and the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- The results for the quarter ended 31st March 2025 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
- Figures for the previous periods /year have been regrouped/reclassified wherever necessary.
- The company is pleased to announce that it has been awarded the WHO Certificate, effective as of the date of this results release.

For Vista Pharmaceuticals Limited



Dhananjaya Alli
Whole Time Director
(DIN:00610909)

Place:Hyderabad
Date:30.05.2025




Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 31/03/2025				
(Rs. In lakhs)				
S No	Particulars	Note No.	As at 31st March 2025 (Audited)	As at 31st March 2024 (Audited)
I.	ASSETS			
	Non-current assets			
(a)	Property, Plant and Equipment	2.1	915.07	976.50
(b)	Capital work-in-progress	2.2 (a)	1,013.53	981.92
(c)	Intangible assets	2.2 (b)	955.30	955.30
(d)	Financial Assets			
	(i) Investments	2.3	4.54	2.07
	(ii) Other Financial Assets	2.4	13.74	13.15
	(iii) Trade Receivables	2.7	1,015.16	1,009.33
(e)	Deferred tax assets (Net)	2.12	437.28	330.90
(f)	Other Non-Current Assets	2.5	198.50	198.50
	Total Non - Current Assets		4,553.13	4,467.67
	Current assets			
(a)	Inventories	2.6	822.01	678.61
(b)	Financial assets			
	(i) Investments			
	(ii) Trade receivables	2.7	339.28	418.81
	(iii) Cash and Bank equivalents	2.8	73.33	9.44
(c)	Other current assets	2.5	241.20	223.38
	Total Current Assets		1,475.82	1,330.24
	Total Assets		6,028.95	5,797.90
II	EQUITY AND LIABILITIES			
	Equity			
(a)	Equity Share capital	2.9	1,231.04	943.30
(b)	Other equity	2.10	3,311.22	3,102.93
	Total Equity		4,542.25	4,046.23
	Liabilities			
	Non-current liabilities			
(a)	Financial Liabilities			
	(i) Borrowings	2.11	237.97	293.29
	(ii) Other financial liabilities			-
(b)	Deferred tax liabilities (Net)			-
(c)	Provisions	2.15	12.14	9.15
	Total Non - Current Liabilities		250.11	302.44
	Current liabilities			
(a)	Financial Liabilities			
	(i) Borrowings	2.11	502.47	503.19
	(ii) Trade payables	2.13		
	-Total outstanding dues of micro enterprises and small enterprises		5.71	5.57
	-Total outstanding dues of Creditors other than micro enterprises and small enterprises		553.78	734.96
	(iii) Other financial liabilities	2.14	-	5.30
(b)	Income tax liabilities (net)			-
(c)	Provisions	2.15	0.58	-
(d)	Other Current Tax Liabilities	2.16	174.04	200.21
	Total Current Liabilities		1,236.58	1,449.23
	Total Equity and Liabilities		6,028.94	5,797.90
The accompanying Significant accounting policies and notes form an integral part of the Standalone financial statements.				
			For and on behalf of Board	
				
			Dr.Dhananjaya Alli Whole Time Director (DIN:00610909)	
Place : Hyderabad				
Date : 30-05-2025				



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com


STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST MARCH, 2025

(Rs.in Lakhs)

Particulars	March ,2025	March ,2024
Cash Flows from Operating Activities		
Net profit before tax	(528.98)	(517.74)
Adjustments for :		
Depreciation and amortization expense	73.81	71.97
Gain on investments carried at fair value through profit or loss	2.47	0.35
Gain or Loss on Defined Benefit Plans	0.38	(0.06)
Interest & Finance Charges Paid	96.40	121.98
Operating profit before working capital changes	(355.92)	(323.50)
Movements in Working Capital		
(Increase)/Decrease in Inventories	(143.40)	89.06
(Increase)/Decrease in Other financial assets	(3.06)	0.00
(Increase)/Decrease in Trade Receivables	73.69	(303.05)
(Increase)/Decrease in Other Current Assets	(17.81)	82.52
(Increase)/Decrease in Other Non Current Assets	0.00	(0.88)
Increase/(Decrease) in Trade Payables	(181.04)	(39.73)
Increase/(Decrease) in Other financial liabilities	(5.30)	0.00
Increase/(Decrease) in Other Current liabilities	(26.17)	1.04
Increase/(Decrease) in Other Non Current liabilities	0.00	0.00
Increase/(Decrease) in Provisions	3.56	3.13
Changes in Working Capital	(299.53)	(167.90)
Cash generated from operations	(655.45)	(491.40)
Direct Taxes Paid	(43.01)	-
Net Cash from operating activities (A)	(698.46)	(491.40)
Cash flows from Investing Activities		
Purchase of Fixed Assets (Including CWIP)	(44.00)	(78.99)
Intangible Assets	0.00	0.00
Net Cash used in Investing Activities	(44.00)	(78.99)
Cash flows from/(used in) Financing Activities		
Issue of Share Capital	1,438.70	960.83
Issue of Share Warrants	(479.92)	(134.45)
Proceeds from Long term borrowings	(55.32)	(224.65)
Repayment/Proceeds of/from Short-term borrowings	(0.72)	79.69
Interest paid	(96.40)	(121.98)
Net Cash used in Financing Activities	806.35	559.44
Net Increase/(Decrease) in cash and cash equivalents	63.89	(10.95)
Cash and Cash equivalents at the beginning of the year	9.44	20.40
Cash and Cash equivalents at the ending of the year	73.33	9.44

The accompanying Significant accounting policies and notes form an integral part of the Standalone financial statements.

For and on behalf of Board



Dr.Dhananjaya Alli
Whole Time Director
(DIN:00610909)

Place : Hyderabad

Date : 30-05-2025



A.M REDDY & D.R REDDY
Chartered Accountants

Independent Auditor's Review Report on Audited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

Report on the audit of Standalone Financial Results

Opinion

We have audited the accompanying "Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2025" ("Statement") of VISTA PHARMACEUTICALS LIMITED (the "Company"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued

*H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 | Phone No: 08554-231666
B.O H.No 3-6-640/11C, Fourth Floor, Street No 9, Himayat Nagar , Hyderabad 500 029 | Phone No : 040-40077393
Mobile No: 9848032382 Email ID: rkreddy1999@yahoo.com*

by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section-133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For A.M REDDY & D.R REDDY
Chartered Accountants
Firms Registration No: 009068S


D. Rama Krishna Reddy
Partner
Membership No. 209211
UDIN: 25209211BMJBOB8271
Place: Hyderabad
Date: May 30, 2025

